Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
用户QRAHz7LcpZFU
2小时前
14
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-03-24 14:35:47 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

